These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 33392261)
1. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening. Abdusalam AAA; Murugaiyah V Front Mol Biosci; 2020; 7():603037. PubMed ID: 33392261 [TBL] [Abstract][Full Text] [Related]
5. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249 [TBL] [Abstract][Full Text] [Related]
6. Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic. Muteeb G; Alshoaibi A; Aatif M; Rehman MT; Qayyum MZ Appl Biol Chem; 2020; 63(1):79. PubMed ID: 33251389 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation. Bepari AK; Reza HM PeerJ; 2021; 9():e11261. PubMed ID: 33954055 [TBL] [Abstract][Full Text] [Related]
8. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases. Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022 [TBL] [Abstract][Full Text] [Related]
9. Identification of Novel Drug Candidates for the Inhibition of Catalytic Cleavage Activity of Coronavirus 3CL-like Protease Enzyme. Gurung AB; Al-Anazi KM; Ali MA; Lee J; Farah MA Curr Pharm Biotechnol; 2022; 23(7):959-969. PubMed ID: 34097590 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening. Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740 [TBL] [Abstract][Full Text] [Related]
11. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2. Maurya SK; Maurya AK; Mishra N; Siddique HR J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594 [TBL] [Abstract][Full Text] [Related]
12. Structure-based virtual screening of bioactive compounds from Indonesian medical plants against severe acute respiratory syndrome coronavirus-2. Gani MA; Nurhan AD; Maulana S; Siswodihardjo S; Shinta DW; Khotib J J Adv Pharm Technol Res; 2021; 12(2):120-126. PubMed ID: 34159141 [TBL] [Abstract][Full Text] [Related]
13. Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CL Jukič M; Janežič D; Bren U Molecules; 2020 Dec; 25(24):. PubMed ID: 33316996 [TBL] [Abstract][Full Text] [Related]
14. Virtual screening and molecular simulation study of natural products database for lead identification of novel coronavirus main protease inhibitors. Tripathi N; Goel B; Bhardwaj N; Sahu B; Kumar H; Jain SK J Biomol Struct Dyn; 2022 May; 40(8):3655-3667. PubMed ID: 33213294 [TBL] [Abstract][Full Text] [Related]
15. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation. Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783 [TBL] [Abstract][Full Text] [Related]
16. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases. Kumar V; Roy K SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892 [TBL] [Abstract][Full Text] [Related]
17. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
18. Integrating virtual screening, pharmacoinformatics profiling, and molecular dynamics: identification of promising inhibitors targeting 3CLpro of SARS-CoV-2. Mohammad A; Zheoat A; Oraibi A; Manaithiya A; S Almaary K; Allah Nafidi H; Bourhia M; Kilani-Jaziri S; A Bin Jardan Y Front Mol Biosci; 2023; 10():1306179. PubMed ID: 38516396 [No Abstract] [Full Text] [Related]
19. QSAR based virtual screening derived identification of a novel hit as a SARS CoV-229E 3CL Jawarkar RD; Bakal RL; Zaki MEA; Al-Hussain S; Ghosh A; Gandhi A; Mukerjee N; Samad A; Masand VH; Lewaa I Arab J Chem; 2022 Jan; 15(1):103499. PubMed ID: 34909066 [TBL] [Abstract][Full Text] [Related]
20. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme. Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]